BACKGROUND: Colistin is uncommonly used in clinical practice; however, the emergence of multidrug-resistant organisms has rekindled interest in this potentially toxic therapeutic option. The present study describes the authors' experience with colistin in the management of patients who were infected with metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa within the Calgary Health Region (Calgary, Alberta). METHOD: Adult patients who received colistimethate sodium (colistin) between January 2000 and December 2005 were identified via pharmacy records, and their charts were reviewed retrospectively. Patients with cystic fibrosis were excluded. Patient demographics, clinical course and relevant laboratory data were extracted. RESULTS: Twenty-eight courses of colistin were received by 22 patients. The majority of these treatments were directed at MBL-producing Pseudomonas. One-half of the patients received nebulized colistin. Intravenous (IV) colistin was administered to 12 patients for a mean +/- SD of 14.7+/-13.8 days (range 3.7 to 46 days). The highest IV dose used was 125 mg every 6 h or 6 mg/kg/day. Eight of 12 patients (67%) treated with IV colistin responded either fully or partially. Two patients received IV colistin as outpatients. Adverse effects considered to be due to colistin included drug fever, nephrotoxicity and neurotoxicity. Five of nine patients (56%) who had complete data available for evaluation had at least a doubling of creatinine levels from baseline. CONCLUSION: Patients in the present study received both IV and nebulized colistin for multidrug-resistant P aeruginosa. The use of IV colistin was associated with a favourable response, but mild nephrotoxicity occurred in two-third of patients. It was concluded that colistin may be a useful drug when choices are limited.
BACKGROUND: Colistin is uncommonly used in clinical practice; however, the emergence of multidrug-resistant organisms has rekindled interest in this potentially toxic therapeutic option. The present study describes the authors' experience with colistin in the management of patients who were infected with metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa within the Calgary Health Region (Calgary, Alberta). METHOD: Adult patients who received colistimethate sodium (colistin) between January 2000 and December 2005 were identified via pharmacy records, and their charts were reviewed retrospectively. Patients with cystic fibrosis were excluded. Patient demographics, clinical course and relevant laboratory data were extracted. RESULTS: Twenty-eight courses of colistin were received by 22 patients. The majority of these treatments were directed at MBL-producing Pseudomonas. One-half of the patients received nebulized colistin. Intravenous (IV) colistin was administered to 12 patients for a mean +/- SD of 14.7+/-13.8 days (range 3.7 to 46 days). The highest IV dose used was 125 mg every 6 h or 6 mg/kg/day. Eight of 12 patients (67%) treated with IV colistin responded either fully or partially. Two patients received IV colistin as outpatients. Adverse effects considered to be due to colistin included drug fever, nephrotoxicity and neurotoxicity. Five of nine patients (56%) who had complete data available for evaluation had at least a doubling of creatinine levels from baseline. CONCLUSION:Patients in the present study received both IV and nebulized colistin for multidrug-resistant P aeruginosa. The use of IV colistin was associated with a favourable response, but mild nephrotoxicity occurred in two-third of patients. It was concluded that colistin may be a useful drug when choices are limited.
Authors: Kevin B Laupland; Michael D Parkins; Deirdre L Church; Daniel B Gregson; Thomas J Louie; John M Conly; Sameer Elsayed; Johann D D Pitout Journal: J Infect Dis Date: 2005-09-26 Impact factor: 5.226
Authors: Johann D D Pitout; Daniel B Gregson; Laurent Poirel; Jo-Ann McClure; Phillip Le; Deirdre L Church Journal: J Clin Microbiol Date: 2005-07 Impact factor: 5.948
Authors: Brent W Gunderson; Khalid H Ibrahim; Laurie B Hovde; Timothy L Fromm; Michael D Reed; John C Rotschafer Journal: Antimicrob Agents Chemother Date: 2003-03 Impact factor: 5.191
Authors: Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson Journal: Clin Infect Dis Date: 2003-10-29 Impact factor: 9.079
Authors: Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos Journal: Crit Care Date: 2003-07-28 Impact factor: 9.097
Authors: Niteen D Karnik; Kannan Sridharan; Sonali P Jadhav; Prashant P Kadam; Raghu K Naidu; Rahul D Namjoshi; Vishal Gupta; Mangesh S Gore; Pallavi V Surase; Preeti R Mehta; Jaideep A Gogtay; Urmila M Thatte; Nithya J Gogtay Journal: Eur J Clin Pharmacol Date: 2013-03-19 Impact factor: 2.953
Authors: Herbert Spapen; Rita Jacobs; Viola Van Gorp; Joris Troubleyn; Patrick M Honoré Journal: Ann Intensive Care Date: 2011-05-25 Impact factor: 6.925
Authors: Patrick M Honore; Rita Jacobs; Stijn Lochy; Elisabeth De Waele; Viola Van Gorp; Jouke De Regt; Geert Martens; Olivier Joannes-Boyau; Willem Boer; Herbert D Spapen Journal: Int J Nephrol Renovasc Dis Date: 2013-06-07
Authors: Aneta Luczkiewicz; Ewa Kotlarska; Wojciech Artichowicz; Katarzyna Tarasewicz; Sylwia Fudala-Ksiazek Journal: Environ Sci Pollut Res Int Date: 2015-08-19 Impact factor: 4.223